Providing Constant Analgesia with OROS® Hydromorphone

Journal of Pain and Symptom Management

Volumn 33, Issue 2 SUPPL., 2007, Pages

  Gupta, Suneel ^a   Sathyan, Gayatri ^a  

^a ALZA CORPORATION   (United States)

Author keywords

chronic pain; Hydromorphone; pharmacokinetics; sustained release

Indexed keywords

HYDROMORPHONE; OROS; UNCLASSIFIED DRUG;

ANALGESIA; ARTICLE; CHRONIC PAIN; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG UTILIZATION; ENVIRONMENTAL FACTOR; MAXIMUM PLASMA CONCENTRATION; OSMOTIC PUMP;

EID: 33846616344     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2006.09.009     Document Type: Article

References (17)

1. International Association for the Study of Pain. How prevalent is chronic pain?. Pain Clin Updates XI 2 (2003) 1-4
2. Drover D.R., Angst M.S., Valle M., et al. Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. Anesthesiology 97 (2002) 827-836
3. Angst M.S., Drover D.R., Lötsch J., et al. Pharmacodynamics of orally administered sustained-release hydromorphone in humans. Anesthesiology 94 (2001) 63-73
4. Data on file. ALZA Corporation, Mountain View, CA.
5. Murray A., and Hagen N.A. Hydromorphone. J Pain Symptom Manage 29 5 Suppl (2005) S57-S66
6. Hill H.F., Coda B.A., Tanaka A., and Schaffer R. Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects. Anesth Analg 72 (1991) 330-336
7. Sarhill N., Walsh D., and Nelson K.A. Hydromorphone: pharmacology and clinical applications in cancer patients. Support Care Cancer 9 (2001) 84-96
8. Durnin C., Hind I.D., Ghani S.P., Yates D.B., and Cross M. Dose proportionality of the pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR). Proc West Pharmacol Soc 44 (2001) 73-74
9. Vallner J.J., Stewart J.T., Kotzan J.A., et al. Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects. J Clin Pharmacol 21 (1981) 152-156
10. ®). A retrospective study. Drug Saf 25 (2002) 1021-1033
11. ® osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain. J Pain Symptom Manage 23 (2002) 355-368
12. ® hydromorphone dose range. Proceedings of the 11th World Congress on Pain. Sydney, Australia, August 21-26, 2005. IASP Press: 691; Abstract 179-P294.
13. OROS® Oral Delivery Technology. Available from. http://www.alza.com/alza/oros Accessed September 16, 2005
14. ® hydromorphone. Presented at the 11th World Congress on Pain. Sydney, Australia, August 21-26, 2005. IASP Press: 632-633; Abstract 1796-P299.
15. Sathyan G., Hu W., and Gupta S.K. Lack of effect of food on the pharmacokinetics of an extended-release oxybutynin formulation. J Clin Pharmacol 41 (2001) 187-192
16. Dmochowski R., Chen A., Sathyan G., et al. Effect of the proton pump inhibitor omeprazole on the pharmacokinetics of extended-release formulations of oxybutynin and tolterodine. J Clin Pharmacol 45 (2005) 961-968
17. Eckenhoff B., Theeuwes F., and Urquhart J. Osmotically activated dosage forms for rate-controlled drug delivery. Pharm Technol 5 (1981) 35-44